Lyell Wealth Management LP Has $3.53 Million Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Lyell Wealth Management LP cut its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 12.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,203 shares of the company’s stock after selling 11,685 shares during the period. Lyell Wealth Management LP owned 0.17% of PROCEPT BioRobotics worth $3,529,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. FMR LLC lifted its position in PROCEPT BioRobotics by 13.0% during the 3rd quarter. FMR LLC now owns 7,553,460 shares of the company’s stock valued at $247,829,000 after purchasing an additional 870,364 shares during the period. Vanguard Group Inc. raised its position in shares of PROCEPT BioRobotics by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,074,891 shares of the company’s stock valued at $133,697,000 after acquiring an additional 385,271 shares during the period. Loomis Sayles & Co. L P raised its position in shares of PROCEPT BioRobotics by 89.8% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,345,454 shares of the company’s stock valued at $44,144,000 after acquiring an additional 636,750 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of PROCEPT BioRobotics by 48.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 923,437 shares of the company’s stock valued at $30,298,000 after acquiring an additional 303,003 shares during the period. Finally, Wellington Management Group LLP acquired a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at approximately $26,404,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 5,306 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $49.95, for a total transaction of $265,034.70. Following the completion of the sale, the executive vice president now owns 47,351 shares of the company’s stock, valued at approximately $2,365,182.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Kevin Waters sold 904 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $50.00, for a total transaction of $45,200.00. Following the completion of the sale, the chief financial officer now owns 33,523 shares of the company’s stock, valued at $1,676,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alaleh Nouri sold 5,306 shares of PROCEPT BioRobotics stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $49.95, for a total value of $265,034.70. Following the sale, the executive vice president now directly owns 47,351 shares of the company’s stock, valued at approximately $2,365,182.45. The disclosure for this sale can be found here. Insiders sold 94,149 shares of company stock valued at $4,653,720 in the last quarter. 19.60% of the stock is currently owned by insiders.

PROCEPT BioRobotics Stock Down 2.4 %

Shares of NASDAQ:PRCT traded down $1.27 during midday trading on Wednesday, hitting $52.48. The stock had a trading volume of 519,732 shares, compared to its average volume of 499,018. PROCEPT BioRobotics Co. has a 12 month low of $24.83 and a 12 month high of $54.79. The company has a quick ratio of 6.77, a current ratio of 7.63 and a debt-to-equity ratio of 0.18. The business’s 50-day simple moving average is $49.19 and its 200-day simple moving average is $42.32. The company has a market cap of $2.67 billion, a P/E ratio of -23.82 and a beta of 1.01.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, February 27th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative net margin of 77.75% and a negative return on equity of 46.59%. The firm had revenue of $43.58 million during the quarter, compared to the consensus estimate of $41.79 million. During the same period in the prior year, the business posted ($0.56) earnings per share. PROCEPT BioRobotics’s quarterly revenue was up 83.3% compared to the same quarter last year. On average, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PRCT shares. Wells Fargo & Company increased their price target on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a research report on Tuesday, January 9th. Truist Financial increased their target price on PROCEPT BioRobotics from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $45.60.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).